Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus | 67 | 2024 | 5887 | 5.670 |
Why?
|
Endocrinology | 25 | 2023 | 441 | 4.560 |
Why?
|
Patient-Centered Care | 23 | 2020 | 1445 | 3.430 |
Why?
|
Diabetes Mellitus, Type 1 | 20 | 2024 | 3446 | 2.110 |
Why?
|
Diabetes Mellitus, Type 2 | 41 | 2023 | 12245 | 1.960 |
Why?
|
Blood Glucose | 24 | 2022 | 6422 | 1.720 |
Why?
|
Primary Health Care | 18 | 2023 | 4735 | 1.650 |
Why?
|
Hypoglycemia | 7 | 2022 | 896 | 1.440 |
Why?
|
Diabetes Complications | 8 | 2018 | 1319 | 1.340 |
Why?
|
Hyperglycemia | 12 | 2024 | 1389 | 1.330 |
Why?
|
Self Care | 10 | 2018 | 800 | 1.200 |
Why?
|
Family Practice | 3 | 2016 | 508 | 1.190 |
Why?
|
Hypoglycemic Agents | 18 | 2022 | 3108 | 1.180 |
Why?
|
Pennsylvania | 13 | 2016 | 615 | 1.100 |
Why?
|
Case Management | 4 | 2013 | 276 | 1.090 |
Why?
|
Insulin | 18 | 2021 | 6608 | 1.070 |
Why?
|
Blood Glucose Self-Monitoring | 10 | 2022 | 475 | 0.940 |
Why?
|
Podiatry | 2 | 2014 | 28 | 0.820 |
Why?
|
Standard of Care | 20 | 2023 | 569 | 0.810 |
Why?
|
Education, Continuing | 1 | 2023 | 115 | 0.790 |
Why?
|
Glucagon | 3 | 2021 | 534 | 0.790 |
Why?
|
Reference Standards | 19 | 2023 | 1010 | 0.760 |
Why?
|
Fellowships and Scholarships | 2 | 2020 | 1134 | 0.750 |
Why?
|
Professional Role | 2 | 2014 | 314 | 0.710 |
Why?
|
Diabetic Ketoacidosis | 5 | 2024 | 252 | 0.710 |
Why?
|
Biomedical Technology | 2 | 2018 | 210 | 0.680 |
Why?
|
Practice Management, Medical | 2 | 2018 | 191 | 0.650 |
Why?
|
Competitive Bidding | 1 | 2019 | 16 | 0.650 |
Why?
|
Attitude of Health Personnel | 6 | 2016 | 3927 | 0.650 |
Why?
|
Reagent Strips | 1 | 2019 | 40 | 0.640 |
Why?
|
Health Educators | 1 | 2018 | 19 | 0.620 |
Why?
|
Health Care Costs | 7 | 2024 | 3242 | 0.620 |
Why?
|
Disease Management | 6 | 2019 | 2533 | 0.620 |
Why?
|
Organizational Innovation | 7 | 2018 | 540 | 0.610 |
Why?
|
Blood Chemical Analysis | 1 | 2019 | 434 | 0.550 |
Why?
|
Patient Care Team | 7 | 2021 | 2519 | 0.550 |
Why?
|
Quality Improvement | 6 | 2023 | 3850 | 0.550 |
Why?
|
Cooperative Behavior | 3 | 2016 | 1512 | 0.550 |
Why?
|
Motivation | 7 | 2017 | 2020 | 0.540 |
Why?
|
Emergency Medical Services | 2 | 2018 | 1936 | 0.530 |
Why?
|
Internet | 4 | 2015 | 3113 | 0.530 |
Why?
|
Humans | 147 | 2024 | 766766 | 0.520 |
Why?
|
Models, Organizational | 7 | 2018 | 548 | 0.510 |
Why?
|
Patient Education as Topic | 7 | 2017 | 2334 | 0.510 |
Why?
|
Models, Economic | 2 | 2016 | 719 | 0.490 |
Why?
|
Islets of Langerhans Transplantation | 2 | 2019 | 747 | 0.490 |
Why?
|
Health Care Reform | 4 | 2013 | 1256 | 0.480 |
Why?
|
Practice Guidelines as Topic | 7 | 2020 | 7431 | 0.450 |
Why?
|
Comprehensive Health Care | 1 | 2015 | 123 | 0.450 |
Why?
|
Career Choice | 1 | 2020 | 768 | 0.440 |
Why?
|
Quality Assurance, Health Care | 4 | 2014 | 2171 | 0.440 |
Why?
|
Telemedicine | 6 | 2021 | 3111 | 0.440 |
Why?
|
Nurses | 3 | 2014 | 2503 | 0.430 |
Why?
|
Societies, Medical | 19 | 2023 | 3957 | 0.420 |
Why?
|
Insulin Infusion Systems | 2 | 2005 | 221 | 0.420 |
Why?
|
Health Plan Implementation | 2 | 2016 | 337 | 0.410 |
Why?
|
Insulin-Secreting Cells | 1 | 2019 | 899 | 0.390 |
Why?
|
United States | 29 | 2024 | 72951 | 0.390 |
Why?
|
Self-Help Groups | 1 | 2013 | 194 | 0.380 |
Why?
|
Health Priorities | 1 | 2014 | 380 | 0.380 |
Why?
|
Physicians | 3 | 2020 | 4591 | 0.380 |
Why?
|
Burnout, Professional | 1 | 2020 | 710 | 0.380 |
Why?
|
Drug Costs | 1 | 2019 | 1195 | 0.370 |
Why?
|
Patient Protection and Affordable Care Act | 3 | 2016 | 1188 | 0.360 |
Why?
|
Health Services | 2 | 2024 | 755 | 0.360 |
Why?
|
Physician Assistants | 1 | 2013 | 190 | 0.350 |
Why?
|
Health Care Surveys | 2 | 2015 | 2425 | 0.350 |
Why?
|
Quality of Health Care | 8 | 2018 | 4306 | 0.340 |
Why?
|
Monitoring, Ambulatory | 3 | 2019 | 357 | 0.320 |
Why?
|
Academic Medical Centers | 2 | 2018 | 2783 | 0.320 |
Why?
|
Organizational Culture | 1 | 2013 | 513 | 0.320 |
Why?
|
Models, Psychological | 1 | 2013 | 823 | 0.310 |
Why?
|
Chronic Disease | 7 | 2016 | 9357 | 0.310 |
Why?
|
Directive Counseling | 1 | 2010 | 171 | 0.310 |
Why?
|
Clinical Trials as Topic | 3 | 2022 | 8045 | 0.290 |
Why?
|
Interviews as Topic | 3 | 2016 | 2741 | 0.280 |
Why?
|
Cholesterol, LDL | 3 | 2012 | 2392 | 0.280 |
Why?
|
Interview, Psychological | 1 | 2010 | 810 | 0.270 |
Why?
|
Perioperative Care | 2 | 2012 | 1043 | 0.270 |
Why?
|
Diabetic Foot | 1 | 2011 | 383 | 0.270 |
Why?
|
Software | 3 | 2019 | 4466 | 0.270 |
Why?
|
Registries | 3 | 2009 | 8351 | 0.260 |
Why?
|
Medical Informatics | 1 | 2013 | 744 | 0.260 |
Why?
|
Length of Stay | 4 | 2016 | 6490 | 0.260 |
Why?
|
Ophthalmology | 2 | 2010 | 560 | 0.260 |
Why?
|
United States Agency for Healthcare Research and Quality | 2 | 2016 | 85 | 0.260 |
Why?
|
Autoantibodies | 2 | 2024 | 2115 | 0.250 |
Why?
|
Research Design | 2 | 2019 | 6207 | 0.250 |
Why?
|
Monitoring, Intraoperative | 1 | 2012 | 947 | 0.250 |
Why?
|
Quality Indicators, Health Care | 2 | 2017 | 1804 | 0.250 |
Why?
|
Medicine | 1 | 2013 | 944 | 0.240 |
Why?
|
Inpatients | 3 | 2012 | 2565 | 0.240 |
Why?
|
Internship and Residency | 2 | 2016 | 5943 | 0.240 |
Why?
|
Patient Satisfaction | 3 | 2013 | 3485 | 0.230 |
Why?
|
Cardiovascular Diseases | 3 | 2023 | 15657 | 0.230 |
Why?
|
Mass Screening | 2 | 2009 | 5454 | 0.210 |
Why?
|
Child Care | 1 | 2023 | 126 | 0.210 |
Why?
|
Blood Pressure | 9 | 2015 | 8533 | 0.200 |
Why?
|
Medication Adherence | 2 | 2014 | 2190 | 0.200 |
Why?
|
Administrative Personnel | 2 | 2014 | 185 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3110 | 0.200 |
Why?
|
Patient Readmission | 1 | 2016 | 3283 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3232 | 0.200 |
Why?
|
Referral and Consultation | 4 | 2021 | 3618 | 0.200 |
Why?
|
Health Promotion | 1 | 2014 | 2209 | 0.200 |
Why?
|
Hyperoxia | 2 | 2015 | 259 | 0.190 |
Why?
|
Female | 41 | 2023 | 396520 | 0.190 |
Why?
|
Cost-Benefit Analysis | 5 | 2019 | 5536 | 0.180 |
Why?
|
Pandemics | 1 | 2020 | 8735 | 0.170 |
Why?
|
Prediabetic State | 2 | 2018 | 547 | 0.170 |
Why?
|
Adult | 36 | 2024 | 223307 | 0.170 |
Why?
|
Consensus | 6 | 2024 | 3208 | 0.170 |
Why?
|
Male | 38 | 2021 | 364142 | 0.160 |
Why?
|
Focus Groups | 4 | 2014 | 1459 | 0.160 |
Why?
|
Ribavirin | 1 | 2001 | 396 | 0.160 |
Why?
|
Delivery of Health Care | 5 | 2021 | 5368 | 0.160 |
Why?
|
Retinal Vessels | 3 | 2015 | 863 | 0.160 |
Why?
|
Cyclic AMP | 4 | 1987 | 1472 | 0.150 |
Why?
|
San Francisco | 1 | 2018 | 166 | 0.150 |
Why?
|
Vasodilation | 2 | 2013 | 969 | 0.150 |
Why?
|
Health Personnel | 3 | 2023 | 3384 | 0.150 |
Why?
|
Pharmacists | 1 | 2021 | 261 | 0.150 |
Why?
|
Eating | 1 | 2005 | 1539 | 0.150 |
Why?
|
Physician-Patient Relations | 1 | 2011 | 3266 | 0.150 |
Why?
|
Needs Assessment | 2 | 2017 | 1140 | 0.150 |
Why?
|
Middle Aged | 31 | 2020 | 223257 | 0.150 |
Why?
|
Continuity of Patient Care | 2 | 2016 | 1077 | 0.150 |
Why?
|
Phosphoenolpyruvate Carboxykinase (GTP) | 2 | 1996 | 40 | 0.150 |
Why?
|
Diabetic Retinopathy | 3 | 2013 | 1300 | 0.140 |
Why?
|
Biotechnology | 1 | 2019 | 283 | 0.140 |
Why?
|
Comorbidity | 4 | 2023 | 10580 | 0.140 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2023 | 713 | 0.140 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3250 | 0.140 |
Why?
|
Endpoint Determination | 1 | 2019 | 592 | 0.140 |
Why?
|
Vasoconstriction | 2 | 2012 | 592 | 0.140 |
Why?
|
Retinal Diseases | 1 | 2023 | 709 | 0.130 |
Why?
|
Interferon-alpha | 1 | 2001 | 910 | 0.130 |
Why?
|
Privacy | 1 | 2018 | 233 | 0.130 |
Why?
|
Nurse's Role | 3 | 2013 | 187 | 0.130 |
Why?
|
Risk Factors | 8 | 2021 | 74881 | 0.130 |
Why?
|
Critical Care | 3 | 2020 | 2714 | 0.130 |
Why?
|
Computers | 1 | 2018 | 589 | 0.130 |
Why?
|
Hypertension | 1 | 2016 | 8616 | 0.130 |
Why?
|
Alkyl and Aryl Transferases | 1 | 1996 | 89 | 0.130 |
Why?
|
Liver Glycogen | 2 | 1986 | 36 | 0.120 |
Why?
|
Wounds and Injuries | 2 | 2007 | 2513 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2017 | 4056 | 0.120 |
Why?
|
Health Services Accessibility | 4 | 2019 | 5514 | 0.120 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2018 | 388 | 0.120 |
Why?
|
Tomography, Optical Coherence | 1 | 2008 | 2937 | 0.120 |
Why?
|
Treatment Outcome | 11 | 2019 | 65273 | 0.120 |
Why?
|
Coronary Artery Bypass | 1 | 2004 | 2188 | 0.120 |
Why?
|
Aged | 21 | 2024 | 171343 | 0.120 |
Why?
|
Confidentiality | 1 | 2018 | 607 | 0.110 |
Why?
|
Nutrition Policy | 1 | 2018 | 467 | 0.110 |
Why?
|
Hyperglycemic Hyperosmolar Nonketotic Coma | 2 | 2024 | 30 | 0.110 |
Why?
|
Obesity | 3 | 2023 | 13090 | 0.110 |
Why?
|
Telecommunications | 1 | 2014 | 79 | 0.110 |
Why?
|
Congresses as Topic | 1 | 2018 | 811 | 0.110 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 434 | 0.110 |
Why?
|
Ambulatory Care Facilities | 1 | 2019 | 939 | 0.110 |
Why?
|
Health Behavior | 3 | 2023 | 2649 | 0.110 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1120 | 0.110 |
Why?
|
Nurse-Patient Relations | 1 | 2013 | 101 | 0.100 |
Why?
|
Practice Management | 1 | 2013 | 37 | 0.100 |
Why?
|
Hepatitis C, Chronic | 1 | 2001 | 1033 | 0.100 |
Why?
|
Diabetic Angiopathies | 3 | 2015 | 806 | 0.100 |
Why?
|
History, 21st Century | 1 | 2018 | 1574 | 0.100 |
Why?
|
Adaptation, Psychological | 2 | 2013 | 2662 | 0.100 |
Why?
|
Medicare | 2 | 2024 | 6820 | 0.090 |
Why?
|
Lipoproteins, LDL | 2 | 2013 | 642 | 0.090 |
Why?
|
Curriculum | 2 | 2016 | 3783 | 0.090 |
Why?
|
Calcium | 4 | 2006 | 5783 | 0.090 |
Why?
|
Guidelines as Topic | 1 | 2018 | 1394 | 0.090 |
Why?
|
Diagnostic Self Evaluation | 1 | 2013 | 228 | 0.090 |
Why?
|
Nurse Practitioners | 1 | 2014 | 270 | 0.090 |
Why?
|
Risk Assessment | 3 | 2019 | 24295 | 0.090 |
Why?
|
Perioperative Period | 1 | 2012 | 252 | 0.090 |
Why?
|
Withholding Treatment | 1 | 2014 | 619 | 0.090 |
Why?
|
Coronary Disease | 3 | 2015 | 5915 | 0.090 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 1673 | 0.090 |
Why?
|
Young Adult | 7 | 2021 | 59939 | 0.080 |
Why?
|
Infusions, Intravenous | 2 | 2012 | 2228 | 0.080 |
Why?
|
Nursing Homes | 1 | 2017 | 1084 | 0.080 |
Why?
|
Injections, Subcutaneous | 1 | 2011 | 684 | 0.080 |
Why?
|
1-Methyl-3-isobutylxanthine | 2 | 1986 | 100 | 0.080 |
Why?
|
Education, Nursing, Continuing | 1 | 2009 | 69 | 0.080 |
Why?
|
Photic Stimulation | 2 | 2013 | 1989 | 0.080 |
Why?
|
Electrical Equipment and Supplies | 1 | 2009 | 28 | 0.080 |
Why?
|
Cost of Illness | 2 | 2024 | 1949 | 0.080 |
Why?
|
Adolescent | 8 | 2023 | 88904 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2023 | 2306 | 0.080 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 949 | 0.080 |
Why?
|
Kidney Transplantation | 1 | 2003 | 4278 | 0.080 |
Why?
|
Health Maintenance Organizations | 2 | 2002 | 656 | 0.080 |
Why?
|
Medicaid | 2 | 2014 | 2836 | 0.080 |
Why?
|
Glasgow Coma Scale | 2 | 2007 | 574 | 0.080 |
Why?
|
Antiviral Agents | 1 | 2001 | 3070 | 0.080 |
Why?
|
Diabetes, Gestational | 1 | 2018 | 1263 | 0.080 |
Why?
|
Mentors | 1 | 2014 | 671 | 0.080 |
Why?
|
Physicians, Primary Care | 1 | 2014 | 622 | 0.070 |
Why?
|
Postoperative Complications | 2 | 2016 | 15831 | 0.070 |
Why?
|
Islets of Langerhans | 2 | 2024 | 1350 | 0.070 |
Why?
|
Lactates | 2 | 1986 | 398 | 0.070 |
Why?
|
Self Efficacy | 2 | 2009 | 643 | 0.070 |
Why?
|
Preoperative Care | 2 | 2009 | 2253 | 0.070 |
Why?
|
Qualitative Research | 3 | 2014 | 3138 | 0.070 |
Why?
|
Quality of Life | 4 | 2019 | 13476 | 0.070 |
Why?
|
Overweight | 1 | 2018 | 2446 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 10745 | 0.070 |
Why?
|
Inservice Training | 1 | 2009 | 374 | 0.070 |
Why?
|
Urban Population | 1 | 2015 | 2040 | 0.070 |
Why?
|
Sciatic Nerve | 1 | 1990 | 627 | 0.070 |
Why?
|
Injury Severity Score | 2 | 2007 | 1049 | 0.070 |
Why?
|
New York City | 1 | 2009 | 736 | 0.070 |
Why?
|
Sebum | 1 | 2006 | 17 | 0.070 |
Why?
|
Postprandial Period | 2 | 2006 | 320 | 0.070 |
Why?
|
Sebaceous Glands | 1 | 2006 | 42 | 0.070 |
Why?
|
Oxaloacetates | 1 | 1985 | 5 | 0.060 |
Why?
|
Quinolinic Acids | 1 | 1985 | 15 | 0.060 |
Why?
|
Theophylline | 1 | 1986 | 133 | 0.060 |
Why?
|
Nursing Staff, Hospital | 1 | 2009 | 350 | 0.060 |
Why?
|
Pressure Ulcer | 1 | 2007 | 158 | 0.060 |
Why?
|
Drug Therapy, Combination | 3 | 2007 | 6307 | 0.060 |
Why?
|
Fenofibrate | 1 | 2006 | 87 | 0.060 |
Why?
|
Protein Kinase C | 1 | 1990 | 1206 | 0.060 |
Why?
|
Decision Making | 2 | 2018 | 3951 | 0.060 |
Why?
|
Drug Utilization | 1 | 2012 | 1187 | 0.060 |
Why?
|
Pyruvates | 1 | 1985 | 84 | 0.060 |
Why?
|
Health Services Research | 1 | 2013 | 1811 | 0.060 |
Why?
|
Faculty, Medical | 1 | 2014 | 1226 | 0.060 |
Why?
|
3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1985 | 50 | 0.060 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 1986 | 213 | 0.060 |
Why?
|
Survival Analysis | 1 | 2017 | 10100 | 0.060 |
Why?
|
Hyperlipidemias | 2 | 2007 | 771 | 0.060 |
Why?
|
PPAR alpha | 1 | 2006 | 177 | 0.060 |
Why?
|
Enteral Nutrition | 1 | 2011 | 802 | 0.060 |
Why?
|
Brachial Artery | 1 | 2006 | 373 | 0.060 |
Why?
|
Gluconeogenesis | 1 | 1985 | 186 | 0.060 |
Why?
|
Retrospective Studies | 7 | 2021 | 81635 | 0.060 |
Why?
|
Education, Medical, Continuing | 1 | 2010 | 830 | 0.060 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2005 | 355 | 0.060 |
Why?
|
Database Management Systems | 1 | 2005 | 263 | 0.060 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 1990 | 1121 | 0.060 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2418 | 0.060 |
Why?
|
United States Department of Veterans Affairs | 1 | 2009 | 937 | 0.060 |
Why?
|
Reference Values | 2 | 2008 | 4913 | 0.060 |
Why?
|
Hemostasis | 1 | 2006 | 467 | 0.050 |
Why?
|
Information Dissemination | 1 | 2012 | 1142 | 0.050 |
Why?
|
Glycemic Index | 1 | 2006 | 400 | 0.050 |
Why?
|
Glucose | 3 | 2006 | 4340 | 0.050 |
Why?
|
Lipolysis | 1 | 1985 | 211 | 0.050 |
Why?
|
Counseling | 1 | 2011 | 1552 | 0.050 |
Why?
|
Medical Records | 1 | 2009 | 1408 | 0.050 |
Why?
|
Morbidity | 1 | 2009 | 1754 | 0.050 |
Why?
|
Glucose Tolerance Test | 1 | 2006 | 1180 | 0.050 |
Why?
|
PPAR gamma | 1 | 2006 | 484 | 0.050 |
Why?
|
Administration, Oral | 2 | 2008 | 4018 | 0.050 |
Why?
|
Cataract | 1 | 2009 | 837 | 0.050 |
Why?
|
Child Day Care Centers | 1 | 2023 | 122 | 0.050 |
Why?
|
Clinical Competence | 2 | 2016 | 4858 | 0.050 |
Why?
|
International Cooperation | 1 | 2009 | 1434 | 0.050 |
Why?
|
Documentation | 1 | 2009 | 914 | 0.050 |
Why?
|
Pilot Projects | 3 | 2015 | 8728 | 0.050 |
Why?
|
Rats, Inbred Strains | 3 | 1990 | 2078 | 0.050 |
Why?
|
Social Support | 1 | 2012 | 2191 | 0.050 |
Why?
|
Hypolipidemic Agents | 1 | 2006 | 609 | 0.050 |
Why?
|
Aging | 1 | 2020 | 8731 | 0.050 |
Why?
|
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 3 | 1986 | 7 | 0.050 |
Why?
|
Epinephrine | 1 | 1985 | 782 | 0.050 |
Why?
|
Dietary Carbohydrates | 1 | 2006 | 896 | 0.050 |
Why?
|
Rats | 8 | 2000 | 23717 | 0.050 |
Why?
|
Urinary Tract Infections | 1 | 2007 | 804 | 0.050 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 15416 | 0.040 |
Why?
|
Ultrasonography, Doppler, Pulsed | 1 | 2000 | 19 | 0.040 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2006 | 1494 | 0.040 |
Why?
|
Liver | 4 | 1996 | 7571 | 0.040 |
Why?
|
Aged, 80 and over | 6 | 2020 | 59550 | 0.040 |
Why?
|
Regional Blood Flow | 2 | 2013 | 1478 | 0.040 |
Why?
|
Glaucoma | 1 | 2009 | 1194 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2007 | 4853 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2005 | 2108 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10384 | 0.040 |
Why?
|
Surgical Procedures, Operative | 1 | 2009 | 1931 | 0.040 |
Why?
|
Incidence | 1 | 2016 | 21525 | 0.040 |
Why?
|
Health Status | 2 | 2009 | 4087 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2010 | 3692 | 0.040 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2004 | 1721 | 0.040 |
Why?
|
Enzyme Activation | 2 | 1996 | 3587 | 0.040 |
Why?
|
Diabetic Nephropathies | 1 | 2004 | 975 | 0.040 |
Why?
|
Postoperative Care | 1 | 2004 | 1480 | 0.040 |
Why?
|
Arrhythmias, Cardiac | 1 | 2007 | 2258 | 0.040 |
Why?
|
Treatment Failure | 1 | 2003 | 2659 | 0.040 |
Why?
|
Mid-Atlantic Region | 1 | 2016 | 24 | 0.040 |
Why?
|
Culture Media | 1 | 2019 | 893 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2008 | 5306 | 0.030 |
Why?
|
Preconception Care | 1 | 2018 | 143 | 0.030 |
Why?
|
Transferases | 1 | 1996 | 71 | 0.030 |
Why?
|
Farnesyltranstransferase | 1 | 1996 | 70 | 0.030 |
Why?
|
Arteriosclerosis | 1 | 2000 | 1055 | 0.030 |
Why?
|
Chromones | 1 | 1996 | 148 | 0.030 |
Why?
|
Respiration, Artificial | 1 | 2007 | 2727 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3430 | 0.030 |
Why?
|
8-Bromo Cyclic Adenosine Monophosphate | 2 | 1986 | 73 | 0.030 |
Why?
|
Body Mass Index | 3 | 2009 | 13050 | 0.030 |
Why?
|
Pneumonia | 1 | 2007 | 2159 | 0.030 |
Why?
|
Acute Kidney Injury | 1 | 2007 | 1946 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2015 | 22248 | 0.030 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 492 | 0.030 |
Why?
|
Arterioles | 1 | 2015 | 252 | 0.030 |
Why?
|
Child | 5 | 2023 | 80668 | 0.030 |
Why?
|
Pyridines | 1 | 1985 | 2888 | 0.030 |
Why?
|
Kinetics | 3 | 1987 | 6287 | 0.030 |
Why?
|
Sepsis | 1 | 2007 | 2604 | 0.030 |
Why?
|
Survival Rate | 1 | 2007 | 12825 | 0.030 |
Why?
|
Adipose Tissue | 1 | 1985 | 3314 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2018 | 904 | 0.030 |
Why?
|
Morpholines | 1 | 1996 | 584 | 0.030 |
Why?
|
Health Services Needs and Demand | 2 | 2012 | 1404 | 0.030 |
Why?
|
Pluripotent Stem Cells | 1 | 2019 | 808 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2000 | 1794 | 0.020 |
Why?
|
Cardiomyopathies | 1 | 2004 | 2059 | 0.020 |
Why?
|
Goals | 1 | 2017 | 717 | 0.020 |
Why?
|
Mitral Valve | 1 | 2000 | 1473 | 0.020 |
Why?
|
Time Factors | 3 | 2019 | 40149 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2013 | 39309 | 0.020 |
Why?
|
Calcinosis | 1 | 2000 | 1480 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 1996 | 1168 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2001 | 6507 | 0.020 |
Why?
|
Health Expenditures | 1 | 2024 | 2390 | 0.020 |
Why?
|
Heart Rate | 2 | 2013 | 4207 | 0.020 |
Why?
|
Trifluoperazine | 1 | 1990 | 40 | 0.020 |
Why?
|
Polymyxin B | 1 | 1990 | 44 | 0.020 |
Why?
|
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1990 | 56 | 0.020 |
Why?
|
Asthma | 1 | 2010 | 6268 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2019 | 1600 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 1987 | 5690 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2018 | 1422 | 0.020 |
Why?
|
Lactic Acid | 2 | 1986 | 1139 | 0.020 |
Why?
|
Graft Rejection | 1 | 2003 | 4504 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2017 | 1791 | 0.020 |
Why?
|
Diglycerides | 1 | 1990 | 175 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2008 | 20144 | 0.020 |
Why?
|
Blood Flow Velocity | 2 | 2006 | 1374 | 0.020 |
Why?
|
Chromatography, Gel | 1 | 1990 | 634 | 0.020 |
Why?
|
Nursing Education Research | 1 | 2009 | 11 | 0.020 |
Why?
|
Nursing Methodology Research | 1 | 2009 | 64 | 0.020 |
Why?
|
Models, Nursing | 1 | 2009 | 47 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3888 | 0.020 |
Why?
|
Phosphatidylserines | 1 | 1990 | 186 | 0.020 |
Why?
|
Depression | 1 | 2009 | 8228 | 0.020 |
Why?
|
Coronary Circulation | 1 | 2015 | 1602 | 0.020 |
Why?
|
Isoquinolines | 1 | 1990 | 350 | 0.020 |
Why?
|
Pregnancy | 2 | 2023 | 30237 | 0.020 |
Why?
|
Oxygen Consumption | 1 | 2015 | 1874 | 0.020 |
Why?
|
Program Evaluation | 1 | 2017 | 2504 | 0.020 |
Why?
|
Transfection | 1 | 1996 | 5754 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 1996 | 1762 | 0.020 |
Why?
|
Societies | 1 | 2008 | 106 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 54871 | 0.020 |
Why?
|
Writing | 1 | 2009 | 200 | 0.020 |
Why?
|
Hospitalization | 1 | 2007 | 10823 | 0.020 |
Why?
|
Disease Progression | 1 | 2024 | 13640 | 0.020 |
Why?
|
Total Quality Management | 1 | 2008 | 264 | 0.020 |
Why?
|
Health Surveys | 2 | 2010 | 4055 | 0.020 |
Why?
|
Phospholipids | 1 | 1990 | 778 | 0.020 |
Why?
|
Phenylisopropyladenosine | 1 | 1986 | 14 | 0.020 |
Why?
|
Gemfibrozil | 1 | 2006 | 30 | 0.020 |
Why?
|
Models, Educational | 1 | 2009 | 375 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 1996 | 2881 | 0.020 |
Why?
|
Concanavalin A | 1 | 1986 | 189 | 0.020 |
Why?
|
Skin | 1 | 2000 | 4499 | 0.020 |
Why?
|
Aminoquinolines | 1 | 1986 | 105 | 0.020 |
Why?
|
Quinolinic Acid | 1 | 1985 | 67 | 0.020 |
Why?
|
Asparagine | 1 | 1985 | 120 | 0.020 |
Why?
|
Oleic Acid | 1 | 1985 | 89 | 0.020 |
Why?
|
Oleic Acids | 1 | 1985 | 71 | 0.020 |
Why?
|
Phenylephrine | 1 | 1986 | 292 | 0.020 |
Why?
|
Animals | 8 | 2000 | 168930 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 1996 | 3721 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9602 | 0.020 |
Why?
|
Insulin, Long-Acting | 1 | 2005 | 59 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2006 | 861 | 0.010 |
Why?
|
Isotretinoin | 1 | 2006 | 135 | 0.010 |
Why?
|
Hemodynamics | 1 | 2015 | 4188 | 0.010 |
Why?
|
Pyruvic Acid | 1 | 1985 | 205 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1987 | 1431 | 0.010 |
Why?
|
Vasopressins | 1 | 1986 | 358 | 0.010 |
Why?
|
Lipogenesis | 1 | 2006 | 217 | 0.010 |
Why?
|
Insurance Claim Review | 1 | 2008 | 744 | 0.010 |
Why?
|
Community Health Services | 1 | 2008 | 659 | 0.010 |
Why?
|
Thiazolidinediones | 1 | 2006 | 460 | 0.010 |
Why?
|
Cytosol | 1 | 1985 | 887 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2008 | 1437 | 0.010 |
Why?
|
Area Under Curve | 1 | 2006 | 1638 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2008 | 962 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1987 | 3053 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3853 | 0.010 |
Why?
|
Benchmarking | 1 | 2008 | 1056 | 0.010 |
Why?
|
Lipids | 1 | 2012 | 3319 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1996 | 12791 | 0.010 |
Why?
|
Trauma Centers | 1 | 2006 | 950 | 0.010 |
Why?
|
Child, Preschool | 1 | 2023 | 42577 | 0.010 |
Why?
|
Sulfonamides | 1 | 1990 | 1982 | 0.010 |
Why?
|
Cells, Cultured | 1 | 1996 | 18984 | 0.010 |
Why?
|
Piperazines | 1 | 1990 | 2547 | 0.010 |
Why?
|
Ligands | 1 | 2006 | 3275 | 0.010 |
Why?
|
Echocardiography, Doppler, Color | 1 | 2000 | 353 | 0.010 |
Why?
|
Diet | 1 | 2017 | 8088 | 0.010 |
Why?
|
Point-of-Care Systems | 1 | 2008 | 1217 | 0.010 |
Why?
|
Lipoproteins, HDL | 1 | 2002 | 677 | 0.010 |
Why?
|
Metformin | 1 | 2005 | 908 | 0.010 |
Why?
|
Myocardial Contraction | 1 | 2000 | 1516 | 0.010 |
Why?
|
Critical Illness | 1 | 2008 | 2750 | 0.010 |
Why?
|
Protein Binding | 1 | 1987 | 9320 | 0.010 |
Why?
|
Anxiety | 1 | 2009 | 4670 | 0.010 |
Why?
|
Body Weight | 1 | 2005 | 4626 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 26310 | 0.010 |
Why?
|
Prognosis | 2 | 2006 | 29948 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2009 | 14762 | 0.010 |
Why?
|
Heart Valve Diseases | 1 | 2000 | 1029 | 0.010 |
Why?
|
Cholesterol | 1 | 2002 | 2903 | 0.010 |
Why?
|
Signal Transduction | 1 | 1996 | 23619 | 0.010 |
Why?
|
Models, Biological | 1 | 2008 | 9461 | 0.010 |
Why?
|
Logistic Models | 1 | 2006 | 13278 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2000 | 8106 | 0.000 |
Why?
|
Socioeconomic Factors | 1 | 2002 | 7841 | 0.000 |
Why?
|
Algorithms | 1 | 2008 | 14072 | 0.000 |
Why?
|
Severity of Illness Index | 1 | 2000 | 15908 | 0.000 |
Why?
|